Betahistine Mesilate Tablets 6mg/Tablet GMP Manufacture 30tablets/Box

• Customization: Available
• Application: Internal Medicine
• Usage Mode: For oral administration
• Model NO.: 6mg/0.06g
• Suitable for: Adult
• State: Liquid
• Shape: Tablet
• Type: Inorganic Chemicals
• Pharmaceutical Technology: Chemical Synthesis
• Transport Package: Carton
• Specification: 6mg
• Trademark: SHIMEN
• Origin: China
• HS Code: 3004909099
• Production Capacity: 10000000

Product Description

Betahistine Mesilate Tablets 6mg

Properties:This product is a white tablet.
Indications:Dizziness and dizziness associated with the following diseases: Meniere's disease, Meniere's syndrome, vertigo.
Dosage:Usually adults take 1~2 tablets (betahistine mesylate 6~12mg once), 3 times a day after meals, and can be increased or decreased according to age and symptoms.
Adverse reactions:Among the total 2,254 cases, 26 cases (1.15%) reported side effects (clinical survey results after marketing) 1. Gastrointestinal tract: occasional (0.1%-5%) nausea and vomiting. 2. Allergies: occasional (0.1%-5%) rashes.
Contraindications: It is contraindicated in patients with a history of allergy to betahistine mesylate or any of the prescribed excipients.
Precautions:The following patients should be administered with caution: 1. Patients with a history of peptic ulcer or active peptic ulcer. [Due to the histamine-like effect of this product, it may cause gastric acid secretion by affecting H2 receptors] 2. Patients with bronchial asthma. [Due to the histamine-like effect of this product, it may cause respiratory tract constriction by affecting H1 receptors] 3. Patients with adrenal medulloma. [Due to the histamine-like effect of this product, it may cause excessive adrenaline secretion and increase blood pressure]
Medication for Special Populations:Precautions for Children:
This trial was not performed and reliable references are available.

Precautions for pregnancy and lactation:
For pregnant women and women who may become pregnant, the treatment should be given only if the benefits are judged to be more dangerous than dangerous. (The safety of administration in pregnant women has not been established)

Notes for the elderly:
In general, due to the decrease in physiological and metabolic function of the elderly, it is necessary to pay attention to reducing the dose.

Shijiazhuang No.4 Pharmaceutical Co., Ltd. was established in 1948, now it is a large-sized foreign invested enterprise and comprehensive medicine manufacturer in China, the capital is USD58 million, and with more than 3000 employees. The company can manufacture 7 series medicines of more than 100 kinds and specifications including infusions, capsules, granules, tablets, oral liquids and etc with GMP approval by SFDA of China. For the key product of large volume I.V solution, the yearly output has reached more than 1200 million bottles including 40 million bottles packing with the soft plastic bottles in the dosage of 500 ml/ 250 ml /100ml. Some index such as quality, variety, and yearly output are all in the leading position of this field in China.  
The products have been sold to some countries and regions in South America, Africa, and Asia.